Haleon (NYSE:HLN) Upgraded at Argus

Haleon (NYSE:HLN) was upgraded by stock analysts at Argus to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other equities research analysts have also issued reports on the company. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Price Performance

HLN opened at $10.60 on Tuesday. The stock has a fifty day moving average price of $10.52 and a 200 day moving average price of $9.87. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. Haleon has a 1 year low of $8.71 and a 1 year high of $11.42. The stock has a market cap of $47.19 billion, a price-to-earnings ratio of 27.17 and a beta of 0.18.

Institutional Investors Weigh In On Haleon

Large investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Haleon in the fourth quarter valued at approximately $163,529,000. Natixis Advisors LLC grew its stake in Haleon by 429.8% in the 4th quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after buying an additional 8,115,633 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Haleon by 4,315.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock valued at $81,155,000 after buying an additional 7,845,391 shares during the last quarter. Bank of Montreal Can raised its holdings in Haleon by 454.1% in the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after acquiring an additional 6,966,416 shares during the period. Finally, Bank of America Corp DE lifted its position in Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after acquiring an additional 6,669,923 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.